Immune-based Therapies
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
Cancers 2020 August 17 [Link] Haitang Yang, Duo Xu, Zhang Yang, Feng Yao, Heng Zhao, Ralph A Schmid, Ren-Wang Peng Abstract Background: Malignant pleural mesothelioma (MPM) is driven by the inactivation of tumor suppressor genes (TSGs). An unmet need in the field is the translation of the genomic landscape into effective TSG-specific therapies. Methods: We…
Read MoreProgress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma
Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…
Read MoreQuestioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis
Lung Cancer 2020 June 21 [Link] Luca Cantini, Federica Pecci, Alberto Murrone, Marco Tomasetti, Cecilia Copparoni, Ilaria Fiordoliva, Francesca Morgese, Silvia Rinaldi, Paola Mazzanti, Corrado Rubini, Alessia Cimadamore, Francesca Barbisan, Riccardo Giampieri, Marina Scarpelli, Lory Santarelli, Rossana Berardi Abstract Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is…
Read MoreERS/ESTS/EACTS/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma
European Journal of Cardiothoracic Surgery 2020 May 25 [Link] Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen, Charlotte De Bondt, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Dean A Fennell, Francoise Galateau-Salle, Laurent Greillier, Mir Ali Hoda, Walter Klepetko, Aude Lacourt, Phil McElnay,…
Read MoreTargeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.
Cells 2020 April 20 [Link] Nishinaga Y, Sato K, Yasui H, Taki S, Takahashi K, Shimizu M, Endo R, Koike C, Kuramoto N, Nakamura S, Fukui T, Yukawa H, Baba Y, K Kaneko M, Chen-Yoshikawa TF, Kobayashi H, Kato Y, Hasegawa Y Abstract Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis.…
Read MorePermanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy.
Archives of Endocrinology 2020 April 6 [Link] Brilli L, Calabrò L, Campanile M, Pilli T, Agostinis C, Cerase A, Maio M, Castagna M Abstract Checkpoint inhibitors have substantially improved the prognosis for patients with advanced malignancy. Treatment with immunomodulants has the ability to reactivate the immune system against tumor cells, but can also trigger the…
Read MoreEmerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Frontiers in Oncology 2020 March 12 [Link] Cantini L, Hassan R, Sterman DH, Aerts JGJV Abstract Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new treatments to be…
Read MoreImmunotherapy in Malignant Pleural Mesothelioma.
Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most…
Read MorePhotodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.
Cancers 2020 February 27 [Link] Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O Abstract The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that…
Read MoreLurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second-…
Read More